Court of Justice 25 March 2021, Case C-611/16 P: Judgment of the Court (Fourth Chamber) of 25 March 2021 — Xellia Pharmaceuticals ApS, Alpharma LLC, formerly Zoetis Products LLC v European Commission (Appeal — Competition — Agreements, decisions and concerted practices — Pharmaceutical products — Market for antidepressants (citalopram) — Settlement agreements relating to disputes concerning process patents concluded by a manufacturer of originator medicines who is the holder of those patents and manufacturers of generic medicines — Article 101 TFEU — Potential competition — Restriction by object — Characterisation — Calculation of the amount of the fine — Rights of the defence — Reasonable time — Loss of documents due to the passage of time — General duty of care — Regulation (EC) No 1/2003 — Second subparagraph of Article 23(2) — Maximum amount of the fine — Taking into account the business year preceding that in which the European Commission’s decision was adopted — Last full year of normal economic act...
Also known as
European Union · · · 31-05-2021
31.5.2021 EN Official Journal of the European Union C 206/5 Judgment of the Court (Fourth Chamber) of 25 March 2021 — Xellia Pharmaceuticals ApS, Alpharma LLC, formerly Zoetis Products LLC v European Commission (Case C-611/16 P) (1) (Appeal - Competition - Agreements, decisions and concerted practices - Pharmaceutical products - Market for antidepressants (citalopram) - Settlement agreements
Read the full text
This document is published by eur-lex.europa.eu.
Moonlit adds the citation network, article-level links and cross-references, which are available to search for free.
Sign in to Moonlit